Two Sigma Securities’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,335
| Closed | -$245K | – | 1753 |
|
|
2026
Q1 | $245K | Sell |
1,335
-4,095
| -75% | -$755K | 0.03% | 923 |
|
|
2025
Q4 | $956K | Buy |
+5,430
| New | +$887K | 0.13% | 187 |
|
|
2024
Q4 | – | Sell |
-10,659
| Closed | -$1.8M | – | 1767 |
|
|
2024
Q3 | $2.07M | Buy |
+10,659
| New | +$2.23M | 0.03% | 536 |
|
|
2024
Q2 | – | Sell |
-3,000
| Closed | -$652K | – | 2988 |
|
|
2024
Q1 | $647K | Buy |
+3,000
| New | +$703K | 0.01% | 1397 |
|
|
2023
Q3 | – | Sell |
-1,314
| Closed | -$351K | – | 2941 |
|
|
2023
Q2 | $374K | Sell |
1,314
-5,585
| -81% | -$1.66M | 0.01% | 1676 |
|
|
2023
Q1 | $1.92M | Buy |
6,899
+5,755
| +503% | +$1.59M | 0.04% | 538 |
|
|
2022
Q4 | $317K | Sell |
1,144
-1,276
| -53% | -$360K | 0.01% | 1481 |
|
|
2022
Q3 | $646K | Buy |
+2,420
| New | +$514K | 0.02% | 899 |
|
|
2022
Q2 | – | Sell |
-9,873
| Closed | -$2.02M | – | 2225 |
|
|
2022
Q1 | $2.08M | Buy |
9,873
+8,184
| +485% | +$1.78M | 0.07% | 342 |
|
|
2021
Q4 | $405K | Buy |
+1,689
| New | +$434K | 0.02% | 641 |
|
|
2021
Q2 | – | Sell |
-759
| Closed | -$230K | – | 1494 |
|
|
2021
Q1 | $212K | Sell |
759
-393
| -34% | -$106K | 0.01% | 617 |
|
|
2020
Q4 | $282K | Buy |
+1,152
| New | +$297K | 0.01% | 1096 |
|
|
2020
Q3 | – | Sell |
-4,048
| Closed | -$1.13M | – | 1302 |
|
|
2020
Q2 | $1.08M | Buy |
+4,048
| New | +$1.22M | 0.02% | 369 |
|
|
2020
Q1 | – | Sell |
-828
| Closed | -$251K | – | 1399 |
|
|
2019
Q4 | $246K | Sell |
828
-8,152
| -91% | -$2.26M | ﹤0.01% | 1931 |
|
|
2019
Q3 | $2.09M | Buy |
8,980
+1,110
| +14% | +$258K | 0.02% | 583 |
|
|
2019
Q2 | $1.84M | Buy |
7,870
+5,140
| +188% | +$1.19M | 0.02% | 487 |
|
|
2019
Q1 | $645K | Buy |
2,730
+1,975
| +262% | +$622K | 0.01% | 763 |
|
|
2018
Q4 | $227K | Sell |
755
-6,289
| -89% | -$2.01M | ﹤0.01% | 1612 |
|
|
2018
Q3 | $2.49M | Buy |
7,044
+6,133
| +673% | +$2.11M | 0.02% | 607 |
|
|
2018
Q2 | $264K | Sell |
911
-2,891
| -76% | -$813K | ﹤0.01% | 2152 |
|
|
2018
Q1 | $1.04M | Buy |
+3,802
| New | +$1.18M | 0.01% | 1233 |
|
|
2017
Q1 | – | Sell |
-1,856
| Closed | -$526K | – | 899 |
|
|
2016
Q4 | $526K | Buy |
+1,856
| New | +$550K | 0.18% | 136 |
|
|
2016
Q1 | – | Sell |
-1,240
| Closed | -$380K | – | 306 |
|
|
2015
Q4 | $380K | Buy |
+1,240
| New | +$356K | 0.46% | 40 |
|
Other funds holding BIIB
Two Sigma Securities's BIIB Position: Q2 2026 in Review
Two Sigma Securities sold out of Biogen (BIIB) in Q2 2026, closing a stake of 1,335 shares — an estimated $245K sold.
Two Sigma Securities first reported a position in BIIB in Q4 2015 and held it in 23 quarters. The position peaked at $2.49M in Q3 2018. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Two Sigma Securities reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
- Two Sigma Securities sold 1,335 Biogen shares in Q2 2026, an estimated $245K.
- Two Sigma Securities first reported a position in Biogen in Q4 2015 and held it in 23 quarters.
- Two Sigma Securities's Biogen position peaked at $2.49M in Q3 2018.
- 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.